Evolve Your Strategy with TALVEY®
TALVEY® is a first-in-class GPRC5D × CD3 targeting agent1,2
For the treatment of adult patients with RRMM who have received ≥4 prior lines of therapy, including a PI, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).